DGIdb - MELPHALAN Drug Record

MELPHALAN chembl:CHEMBL852 ApprovedAntineoplasticImmunotherapy

Alternate Names:

MELPHALAN
AIKERAN
CB-3025
NSC-8806
SK 15673
NCI-C04853
SK-15673
PHENYLALANINE MUSTARD
ALANINE NITROGEN MUSTARD
NSC-241286
MELFALAN
ALKERAN
L-SARCOLYSIN
L-PHENYLALANINE MUSTARD (L-PAM)
PHENYLALANINE NITROGEN MUSTARD
L-SARCOLYSINE
MELFALANO
P-L-SARCOLYSIN
SARCOLYSIN®
L-PAM
4-(BIS(2-CHLOROETHYL)AMINO)-L-PHENYLALANINE
MLP673
P-N-BIS(2-CHLOROETHYL)AMINO-L-PHENYLALANINE
3-(P-(BIS(2-CHLOROETHYL)AMINO)PHENYL)-L-ALANINE
P-BIS(BETA-CHLOROETHYL)AMINOPHENYLALANINE
MELPHALANUM
L-3-(P-(BIS(2-CHLOROETHYL)AMINO)PHENYL)ALANINE
ALKERAN®
L-PHENYLALANINE MUSTARD
P-DI-(2-CHLOROETHYL)AMINO-L-PHENYLALANINE
P-N,N-BIS(2-CHLOROETHYL)AMINO-L-PHENYLALANINE
3-P-(DI(2-CHLOROETHYL)AMINO)-PHENYL-L-ALANINE
pubchem.compound:460612
drugbank:01042
chembl:CHEMBL852
chemidplus:148-82-3
rxcui:6718

Drug Info:

(3 More Sources)

Publications:

Merryman et al., 1997, Fibrinolytic and coagulant responses to regional limb perfusions of tumor necrosis factor, interferon-gamma, and/or melphalan., Thromb. Haemost.
Chen et al., 1998, Sensitization effect of L-2-oxothiazolidine-4-carboxylate on tumor cells to melphalan and the role of 5-oxo-L-prolinase in glutathione modulation in tumor cells., Biochem. Pharmacol.
Keshelava et al., 2001, Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines., Cancer Res.
Hansson et al., 1991, Sensitization of human melanoma cells to the cytotoxic effect of melphalan by the glutathione transferase inhibitor ethacrynic acid., Cancer Res.
Harkey et al., 2005, Overexpression of glutathione-S-transferase, MGSTII, confers resistance to busulfan and melphalan., Cancer Invest.
Preuss et al., 1996, Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs., Int. J. Cancer
Manusama et al., Toxicity and antitumor activity of interferon gamma alone and in combinations with TNFalpha and melphalan in isolated limb perfusion in the BN175 sarcoma tumor model in rats., Oncol. Rep.
van der Heijden et al., 2005, In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor., Clin. Cancer Res.
Wang et al., 2004, Annexin-I expression modulates drug resistance in tumor cells., Biochem. Biophys. Res. Commun.
Chapman et al., 1994, The suppression of drug-induced apoptosis by activation of v-ABL protein tyrosine kinase., Cancer Res.
Favis R et al., 2011, Genetic variation associated with bortezomib-induced peripheral neuropathy., Pharmacogenet Genomics

MELPHALAN OPLAH

Interaction Score: 6.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9751079

Sources:
NCI
MELPHALAN SLC7A5

Interaction Score: 3.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
MELPHALAN FANCC

Interaction Score: 1.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16243825

Sources:
CIViC
MELPHALAN PLAT

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9031449

Sources:
NCI
MELPHALAN IFNG

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9864423

Sources:
NCI
MELPHALAN CTLA4

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21228734

Sources:
PharmGKB
MELPHALAN CDKN1A

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11507071

Sources:
NCI
MELPHALAN MGMT

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8621235

Sources:
NCI
MELPHALAN GSTP1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1988111 15779864

Sources:
NCI
MELPHALAN ABCC1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14733945

Sources:
NCI
MELPHALAN ABL1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7923130

Sources:
NCI
MELPHALAN NR1H4

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MELPHALAN RORC

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MELPHALAN ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
MELPHALAN TP53

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MELPHALAN NFE2L2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MELPHALAN AR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MELPHALAN EHMT2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MELPHALAN CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

NCI: MELPHALAN

Version: 14-September-2017

Alternate Names:

C633 NCI drug code

Drug Info:

Publications:

Merryman et al., 1997, Fibrinolytic and coagulant responses to regional limb perfusions of tumor necrosis factor, interferon-gamma, and/or melphalan., Thromb. Haemost.

Manusama et al., Toxicity and antitumor activity of interferon gamma alone and in combinations with TNFalpha and melphalan in isolated limb perfusion in the BN175 sarcoma tumor model in rats., Oncol. Rep.

Chen et al., 1998, Sensitization effect of L-2-oxothiazolidine-4-carboxylate on tumor cells to melphalan and the role of 5-oxo-L-prolinase in glutathione modulation in tumor cells., Biochem. Pharmacol.

NCI: L-PAM
- Version: 14-September-2017
Alternate Names:

C633 NCI drug code

Drug Info:

Publications:

Keshelava et al., 2001, Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines., Cancer Res.
PharmGKB: melphalan
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Favis R et al., 2011, Genetic variation associated with bortezomib-induced peripheral neuropathy., Pharmacogenet Genomics
CIViC: MELPHALAN
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

van der Heijden et al., 2005, In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor., Clin. Cancer Res.
TTD: Melphalan
- Version: 2020.06.01
Alternate Names:

D00FGO TTD Drug ID

Drug Info:

Publications:
DTC: MELPHALAN
- Version: 02-September-2020
Alternate Names:

CHEMBL852 ChEMBL Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL852
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

MELPHALAN Drug Record

MELPHALAN chembl:CHEMBL852 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9751079

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16243825

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9031449

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9864423

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21228734

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11507071

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8621235

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1988111 15779864

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14733945

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7923130

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Interaction Types & Directionality:

n/a

PMIDs:
9751079

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16243825

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
9031449

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9864423

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
21228734

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11507071

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8621235

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
1988111 15779864

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
14733945

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
7923130

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

C633 NCI drug code

Alternate Names:

C633 NCI drug code

Publications:

Keshelava et al., 2001, Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines., Cancer Res.

Publications:

Favis R et al., 2011, Genetic variation associated with bortezomib-induced peripheral neuropathy., Pharmacogenet Genomics

Publications:

van der Heijden et al., 2005, In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor., Clin. Cancer Res.

Alternate Names:

D00FGO TTD Drug ID

Alternate Names:

CHEMBL852 ChEMBL Drug ID